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The seventh Scandinavian COPD Research Symposium
was held on 18–19 November 2016 at Scandic
Holmenkollen Park Hotel, Oslo, Norway. Since the
first meeting in 2004, the purpose of these Symposia
have been to allow young researchers from Denmark,
Finland, Norway and Sweden to present their research,
thereby also facilitating networking, collaboration and
stimulating future research in the field of COPD. Ten
young scientists from our countries presented their
research, and three state-of the art lectures covered
the areas Biomarkers and Inflammation in COPD,
E-cigarettes and COPD, and Imaging in COPD.
Within the topics of each state-of-the-art the lecturers
held in-depth discussions with the participants on the
second day of the meeting. The meeting was gener-
ously supported by grants from Boehringer Ingelheim,
which also made publication of this supplement to
European Clinical Respiratory Journal possible.
State-of-the art abstracts
Biomarkers and inflammation in COPD
Jörgen Vestbo, Copenhagen, Denmark
Professor Jörgen Vestbo
Division of Infection,
Immunity and Respiratory Medicine,
University of Manchester, UK
jorgen.vestbo@manchester.ac.uk
There is a need for biomarkers in COPD – in order to
evaluate disease activity, to characterise disease pheno-
types and endotypes and to evaluate risk of exacerbations
and complications such as comorbidities. Not surpris-
ingly, markers of systemic inflammation have been the
target of research as COPD is seen as a disease where
inflammation has been part of the definition until now
and where easily accessible biomarkers are available.
The main biomarkers studied have been fibrinogen
hs-CRP, white blood cell count and differential count
(eosinophils), as well as by-products resulting from
inflammation, not least markers of matrix remodelling
and breakdown. Most studies have shown that markers
of systemic inflammation have independent prognostic
value regarding exacerbations, hospitalisation and mor-
tality, although studies with fairly dubious associations
can be found. As a result of studies on fibrinogen, the
US Food and Drug Administration (FDA) has decided
to approve fibrinogen as the first biomarker in COPD
for enriching controlled trials using exacerbations as
primary outcome. None of these markers of systemic
inflammation seem to reflect ongoing disease activity
(when measured as FEV1 decline), but design of stu-
dies of FEV1 decline have inherent biases as a result of
the variety of trajectories that can lead to clinical
COPD. Many of the associations found may also reflect
the well-known relationship between smoking and sys-
temic inflammation. Lately, eosinophils have been seen
as ‘the new black’ in COPD research. Fairly limited
prospective data exist to evaluate the value of eosino-
phils in predicting response to inhaled (and systemic)
corticosteroids in COPD. The issue of determining
relevant cut-offs is also unresolved.
Systemic inflammation is now known to be present
in a subset of COPD patients, to be associated with
poor prognosis, but is not associated with subsequent
FEV1 decline. Other biomarkers may have larger
potential in this respect. Overall, this research field is
still fairly open.
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Background: Public health officials have supported the
use of electronic (e)-cigarettes to reduce harm amongst
nicotine-addicted cigarette users. However, the lung
health effects of e-cigarettes remain unknown and
long-term clinical studies in humans will take decades
to complete. To assess their impact in a more timely
manner, this study exposed mouse lung and normal
human airway epithelial cells to aerosolised nicotine-
free and nicotine-containing e-cigarette fluid.
Methods: Mice were exposed to aerosolised phosphate-
buffered saline, nicotine-free or nicotine-containing
e-cigarette solution, 1 h daily for 4 months. Normal
human bronchial epithelial (NHBE) cells cultured at an
air–liquid interface were exposed to e-cigarette vapours or
nicotine solutions using a Vitrocell smoke exposure robot.
Results: Chronic exposure to nicotine-containing
e-cigarette aerosol increased airway hyper-reactivity,
distal airspace enlargement, mucin production, cyto-
kine and protease expression. Inhalation of nicotine-
free e-cigarette aerosol had no effect on these lung
parameters. NHBE cells exposed to nicotine-containing
e-cigarette vapour showed impaired ciliary beat fre-
quency, airway surface liquid volume, cystic fibrosis
transmembrane regulator and ATP-stimulated K+ ion
conductance and decreased expression of FOXJ1 and
KCNMA1. Exposure of NHBE cells to nicotine for
5 days increased interleukin (IL)-6 and IL-8 secretion.
Conclusions: Chronic exposure to nicotine-containing
e-cigarette fluids induces COPD associated parameters
including cytokine expression, airway hyper-reactivity
and lung tissue destruction. These responses were nico-
tine-dependent both in the mouse lung and in human
airway cells, indicating that inhaled nicotine contri-
butes to airway and lung disease in addition to its
addictive properties. Thus, this study underscores the
potential dangers of chronic nicotine inhalation during
e-cigarette use.
Imaging in COPD
Terttu Harju, Oulu, Finland
Professor Terttu Harju
Respiratory Research, ResearchUnit of InternalMedicine,
Medical Research Center Oulu,
Oulu University Hospital and University of Oulu,
Oulu, Finland
terttu.harju@oulu.fi
Chronic obstructive pulmonary disease (COPD) is a het-
erogenous disease with different clinical phenotypes due
partly to differences in morphologic abnormalities. CT is
not routinely recommended. However, emphysema, air-
way disease, air trapping and pulmonary vascular
abnormalities have all been associated with a number of
important outcomes, including respiratory symptoms,
COPD exacerbations and mortality. A more precise defi-
nition of COPD phenotypemay be helpful in personalised
treatment [1]. Small airway disease is an important major
component of both emphysema-predominant disease and
airway-predominant disease involving larger airways
(bronchi). Isolated small airway disease can also occur as
a primary expression of COPD and CT can be helpful in
identifying signs of inflammatory small airway disease and
small airway obstruction. CT is also needed to identify
interstitial abnormalities likely corresponding to variable
combinations of respiratory bronchiolitis, airspace enlar-
gement with fibrosis, and smoking-related interstitial
fibrosis. Combined pulmonary fibrosis and emphysema
has worse prognosis and more pulmonary hypertension
than phenotypes with no fibrosis. Pulmonary hyperten-
sion can be identified by CT enlargement of the pulmon-
ary artery as determined by a pulmonary artery–aorta
ratio of more than 1, and was recently shown to be an
independent risk factor for COPD exacerbations. CT
measurements of emphysema are considered key surro-
gate endpoints in a1-antitrypsin deficiency clinical trials.
CT has become a critical measurement tool for morpho-
logic phenotyping in large-scale cohort studies.
Pulmonary imaging techniques such as functional CT
and MRI are used in research, to visualise and quantify
regional improvements in ventilation over time in
response to COPD therapy, even in the absence of clini-
cally relevant changes in FEV1, and to study regional gas
trapping and airway morphology as well as in new inter-
ventions for improving regional airflow.
Reference
1. Lynch DA, Austin JHM, Hogg JC, et al. CT-definable
subtypes of chronic obstructive pulmonary disease: a
statement of the Fleischner Society. Radiology.
2015;277:192–205.
Abstracts from other lectures
Ultrastructural and contraction properties of
myofibroblasts in nonsmokers, smokers and COPD
Ninni-Ingrid Nurmos, University of Oulu, Finland
Ninni-Ingrid Nurmos1, Henna Karvonen1,2, Elisa
Lappi-Blanco1,3,4, Terttu Harju1, Magnus Sköld5, Siri
Lehtonen1, and Riitta Kaarteenaho1,6
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Fibroblasts and myofibroblasts are key stromal cells in
fibrotic processes in chronic obstructive pulmonary
disease (COPD).
Our aim was to compare ultrastructural and func-
tional properties of stromal cells isolated from central
and peripheral lung of nonsmokers, smokers and indi-
viduals with COPD. Stromal cells were collected and
cultured from patients undergoing lung cancer surgery.
According to the clinical and lung function data, the
patients were classified as nonsmokers, smokers with
normal lung function and COPD. Myofibroblasts were
investigated by transmission electron microscopy
(TEM) and immunoelectron microscopy (IEM).
Functional properties of cells were analysed by three-
dimensional collagen gel contraction assay. Expression
of alpha smooth muscle actin (α-SMA), a marker for
myofibroblasts, was measured by Western blotting.
Central myofibroblasts from patients with COPD
showed more frequently tandem-like fibronexi, specific
ultrastructures of myofibroblasts, compared to others.
More labels for α-SMA were observed in central than
in peripheral myofibroblasts in individuals without
COPD. Stromal cells from peripheral lung contracted
more than those from central lung, and cells of smo-
kers contracted more than those of nonsmokers.
Peripheral cells of smokers with or without COPD
expressed lower levels of α-SMA compared to non-
smokers. Central fibroblasts of smokers without
COPD expressed less α-SMA than fibroblasts of
nonsmokers.
We concluded that properties of lung fibroblasts
and myofibroblasts vary depending on the
anatomical origin as well as on smoking and
COPD; these phenomena need to be taken into
account when designing research protocols and
drug testing for COPD.
Spirometric criteria and reference values –
consequences on COPD prevalence
Helena Backman, Umeå University, Sweden
Department of Public Health and Clinical Medicine,
Occupational and Environmental Medicine, Umeå
University, Umeå, Sweden
helena.backman@norrbotten.se
Lung function is an extremely important measure in
the evaluation of COPD, and defining normality is
important, both for diagnosis and classification of
severity. The definition of COPD has changed over
time, and the definition of a decreased FEV1/(F)VC
ratio is still under debate.[1–3] Two commonly used
definitions today are the GOLD [4] and ERS/ATS [1]
definitions of a post-bronchodilator FEV1/FVC < 0.7
and FEV1/FVC < LLN (lower limit of normal), respec-
tively, where the LLN is set by the choice of reference
values for spirometry. Simplicity is the main argument
for the fixed ratio criterion advocated by GOLD,[4,5]
while the ERS/ATS points out under-diagnosis among
younger subjects and over-diagnosis among elderly
associated with the fixed ratio criterion.[1,3] The
GOLD criterion has been most frequently used, espe-
cially in the clinics, while the LLN criterion is gaining
ground in epidemiological studies on COPD. Large
population-based studies including spirometry are the
preferred methods to estimate the prevalence of COPD
in a population. Usually, the prevalence is based on
spirometry results, without taking symptoms and expo-
sures into account, and the identified subjects are clas-
sified by disease severity by the level of their FEV1
expressed as % of the corresponding reference value.
The prevalence of COPD is markedly affected by the
choice between slow or forced vital capacity, pre- or
post-bronchodilator spirometry, fixed ratio or LLN as
cut-off, and the choice of reference values.
References
1. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative
strategies for lung function tests. Eur Respir J. 2005
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Symptom experiences in patients with chronic
obstructive pulmonary disease
Vivi Lycke Christensen, University of Oslo, Norway
V. L. Christensen1, T. Rustøen2, B. A. Cooper3, C.
Miaskowski4, A. H. Henriksen5, S. B. Bentsen6, and
A. M. Holm7
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Department of Research and Development, Oslo
University Hospital, Ullevål; Institute of Clinical
Medicine, Faculty of Medicine, University of Oslo;
Lovisenberg Diaconal University College, 2Institute of
Clinical Medicine, Faculty of Medicine, University of
Oslo; Department of Nursing Science, Institute of
Health and Society, University of Oslo, Oslo, Norway,
3Department of Community Health Systems,
4Department of Physiological Nursing, University of
California, San Francisco, CA, USA, 5Department of
Circulation and Medical Imaging, St Olav’s University
Hospital, Trondheim, 6Department of Health Studies,
University of Stavanger, Stavanger, 7Institute of
Clinical Medicine, Faculty of Medicine, University of
Oslo; Department of Respiratory Medicine, Oslo
University Hospital, Rikshospitalet, Oslo, Norway
v.l.christensen@medisin.uio.no
Patients with chronic obstructive pulmonary disease
(COPD) experience multiple co-occurring symptoms.
Previous research has mostly focused on these
patients’ symptom experiences in the advanced stages
of disease.
The aims of this study were to evaluate for differ-
ences in symptom occurrence rates among patients
(n = 267) with moderate, severe, and very severe
COPD, to identify subgroups of patients with distinct
symptom experiences, and to determine if these sub-
groups differed on patient characteristics and disease-
specific quality of life (QOL).
The Memorial Symptom Assessment Scale (MSAS)
was used to evaluate the patients’ symptom experi-
ences based on the occurrence rates of self-reported
symptoms. Binary logistic regression with stage of
disease as an ordinal predictor variable was used to
evaluate for differences in symptom occurrence rates.
Latent class analysis (LCA) was used to identify
subgroups of patients with distinct symptom
experiences.
Regardless of severity of disease, patients reported
an average of 12 co-occurring symptoms. Three sub-
groups of patients were identified and named ‘high’,
‘intermediate’, and ‘low’. Patients in the ‘high’ group
had the highest occurrence rates for psychological
symptoms. These patients were younger, more likely
to be women, had significantly more acute exacerba-
tions in the past year, and reported significantly worse
disease-specific QOL scores.
Findings from this study suggest that patients with
COPD experience a high burden of multiple symptoms
regardless of severity of disease. Patients with a higher
symptom burden may have therapeutic needs that may
not be identified using current classifications that are
based only on respiratory function.
Physical activity and physical capacity in subjects
with chronic obstructive pulmonary disease
Mikael Andersson, Uppsala University, Sweden
Mikael Andersson1,2
1Department of Neuroscience, Physiotherapy, Uppsala
University, Uppsala, Sweden, 2Department of Medical
Science, Respiratory Medicine and Allergology,
Uppsala University, Uppsala, Sweden
mikael.s.andersson@neuro.uu.se
Reduced physical activity levels are common in sub-
jects with COPD and are associated with increased
morbidity and mortality.[1] Pulmonary rehabilitation
should therefore be offered to subjects with a low
physical activity.
As part of my doctoral thesis we have investigated
factors associated with low physical activity levels both
in a selective sample of patients (n = 73) as well as in a
sample of subjects with (n = 403) and without COPD
(n = 659) from the population-based OLIN COPD
study.[2]
In the selective sample,[3] using an objective
method for assessing physical activity, 92% were clas-
sified as physically inactive or sedentary. About 45% of
the variance in physical activity levels were explained
by lung function (22%), walking speed (10%), muscle
strength (7%), and fat-free mass (3%). Age, gender and
systemic inflammation did not contribute to the statis-
tical model.
In the population-based sample,[4] using question-
naires to assess physical activity levels, the prevalence
of low physical activity was higher among subjects with
COPD than without (22.6% vs. 14.6%, respectively). In
4 A. LINDBERG ET AL.
subjects with COPD, the factors most strongly asso-
ciated with low physical activity were older age, OR
1.52 (95% CI 1.12–2.06), a history of heart disease, OR
2.11 (1.10–4.08), and clinically significant fatigue, OR
2.33 (1.31–4.13).
Among non-COPD subjects, obesity was the only
significant factor, OR 2.26 (1.17–4.35).
Our results indicate that attentiveness to patients’
physical function as well as to symptoms of fatigue and
concomitant heart disease may be useful in identifying
subjects in need of pulmonary rehabilitation.
References
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Physical activity and prognosis in COPD patients
Marie J. Waatevik, Haukeland University Hospital,
Norway
Marie Waatevik1, Ane Johannessen2, Francisco Gomez
Real3,4, Marianne Aanerud5, Jon Andrew Hardie3, Per
Sigvald Bakke3, and Tomas Mikal Lind Eagan3,5
1Centre for Clinical research, Haukeland University
Hospital, Bergen, Norway, 2Centre for International
Health, Department of Global Public Health and
Primary Care, University of Bergen, Bergen, Norway,
3Department of Clinical Science, University of Bergen,
Bergen, Norway, 4Department of Gynecology and
Obstetrics, Haukeland University Hospital, Bergen,
Norway, 5Department of Thoracic Medicine,
Haukeland University Hospital, Bergen, Norway
marie.waatevik@helse-bergen.no
The use of six-minute walk test (6MWT) to measure
exercise capacity is a valuable method in both treat-
ment and examination of COPD patients. The 6MWT
provides information on walking distance, oxygen
desaturation and dyspnoea.
The aim of this project is to examine how physical
activity and exercise capacity (measured through the
6MWT), and the functional responses to those, impact
COPD prognosis. We focus on oxygen desaturation
during 6MWT as a predictor for important COPD
outcomes: mortality, frequency of exacerbations,
decline in lung function, and decline in lean body
mass.
A total of 433 COPD patients were included in the
Bergen COPD Cohort Study 2006–2009, and followed
up for 3 years. Patients were characterised with spiro-
metry, bioelectrical impedance measurements,
Charlson co-morbidity score, exacerbation history,
smoking, and arterial blood gases. 370 patients com-
pleted the 6MWT at baseline of the study. Information
on all-cause mortality was collected in 2011.
Patients who experienced oxygen desaturation dur-
ing the 6MWT had more than twofold increased risk of
death; hazard ratio (95% CI) 2.4 (1.2, 5.1), a 50%
increased risk for COPD exacerbations; incidence rate
ratio (95% CI) 1.6 (1.1, 2.2), double the rate of decline
in both FVC and FEV1 (3.3% and 1.7% versus 1.7%
and 0.9% respectively), and manifold increased rate of
loss of lean body mass (0.18 kg m–2 versus 0.03 kg m–2
among those who did not desaturate).[1]
COPD patients that desaturated had significantly
worse prognosis than non-desaturating COPD patients,
for multiple important disease outcomes.[1]
Reference
1. Waatevik M, Johannessen A, Real F, et al. Oxygen desa-
turation in 6-min walk test is a risk factor for adverse
outcomes in COPD. Eur Respir J. 2016;48:82–91.
Mindfulness-based cognitive therapy (MBCT) in
COPD: preliminary results of a randomised
controlled trial
Ingeborg Farver-Vestergaard, Aarhus University
Hospital, Denmark
Ingeborg Farver-Vestergaard1, Anders Løkke Ottesen2,
Elisabeth Bendstrup2, Maja O’Connor1, Robert
Zachariae1
1Unit for Psychooncology and Health Psychology,
Aarhus University and Aarhus University Hospital,
Aarhus, Denmark, 2Department of Respiratory
Diseases and Allergy, Aarhus University Hospital,
Aarhus, Denmark
ifarver@psy.au.dk
Background: Symptoms of anxiety and depression are
prevalent in COPD and are associated with a higher
symptom burden, increased health care utilisation and
lower quality of life.[1] Psychosocial intervention may
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be an effective supplement to already established treat-
ment regimens in COPD.[2]
Aim: We conducted a randomised controlled trial test-
ing the effect of a standardised 8-week mindfulness-
based cognitive therapy (MBCT) programme [3] on
anxiety, depression and disease-specific quality-of-life
in COPD.
Methods: A total of 84 patients with severe to very
severe COPD (age = 67.18 (7.79); women = 57.1%)
were randomised to an intervention group (n = 39),
receiving MBCT as an add-on to a standardised 8-week
pulmonary rehabilitation (PR) programme, or a con-
trol group (n = 45), receiving PR only. Participants
completed questionnaires (the Hospital Anxiety and
Depression Scale (HADS); the COPD Assessment
Test (CAT)) before and after the intervention.
Results: On average, patients in the intervention group
attended 4.08 (SD = 2.74) out of eight MBCT sessions.
The results of a time × group mixed between-within
subjects factorial ANOVA revealed a significant main
interaction effect (F(1,64) = 5.714; p = 0.020) on HADS
scores, corresponding to a medium effect size
(ηp2 = 0.082) and a clinically important mean differ-
ence in the intervention group (>1.5). The main inter-
action effect on CAT scores did not reach statistical
significance (F(1,30) = 1.095, p = 0.304, ηp2 = 0.035).
Conclusion: MBCT may be an effective intervention
for reducing anxiety and depression in COPD. Tele-
based formats of delivery could be considered in the
future with the purpose of minimising missing data
and patient non-attendance.
References
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Elevated sputum vitamin D binding protein levels
in heavy smokers with chronic obstructive
pulmonary disease
Tanja Törölä, University of Helsinki, Finland
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tanja.torola@hus.fi
In our previous proteomic screening study we
showed that sputum vitamin D binding protein
(VDBP) was elevated in chronic obstructive pulmon-
ary disease (COPD).[1] Interestingly, VDBP encod-
ing gene (GC) variants have been associated with
COPD and vitamin D deficiency.[2] The aim of the
current study was to examine the association of
sputum VDBP as well as circulating VDBP and vita-
min D with changes of lung function over a 4-year
follow-up. The biomarker levels and the GC rs4588
and rs7041 genotypes were assessed in non-smokers
(n = 34), heavy smokers without COPD (n = 158) as
well as in smokers with COPD GOLD 2007 stage I
(n = 22) and stage II–III (n = 27). Sputum VDBP
levels were elevated in COPD patients compared to
non-smokers and in COPD stage II–III compared to
smokers without COPD. Furthermore, elevated spu-
tum VDBP significantly correlated with symptoms,
quality of life, and a faster decline of lung function
(FEV1 % predicted and FEV1/FVC %) over 4 years
in patients with COPD stage I. In regression analysis
COPD and smoking were the strongest predictors of
elevated sputum VDBP. Plasma VDBP levels did not
differ between the study groups or correlate with
lung function, but had a weak positive correlation
with vitamin D levels. Plasma VDBP levels were
dependent on the GC rs7041 genotype, though it
was not a confounding factor for sputum VDBP
levels. In conclusion, elevated sputum VDBP may
indicate a faster decline of lung function in COPD.
GC gene genotypes should be considered when eval-
uating VDBP as a potential biomarker of COPD.
References
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Hypogammaglobulinaemia in COPD patients
Siw Lillevik Andreassen, Oslo University Hospital,
Norway
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1Internal Medicine, Drammen Sykehus, 2Oslo
University Hospital, Ullevål, 3Folkehelseinstituttet,
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6University of Oslo (UiO)
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COPD is a complex disease, and there is evidence to
define at least three different phenotypes: overlap or
mixed COPD-asthma, exacerbator, and emphysema-
hyperinflation. In particular, patients with frequent
exacerbation have a high mortality and rapid disease
progression. There may be several reasons why some
COPD patients have frequent exacerbations, both in
genetics, airway damage and the immune system. The
aim of this study is to determine the prevalence of hypo-
gammaglobulinaemia in a cohort of stable COPD
patients and to relate immunoglobulin levels to manifes-
tations of COPD, such as lung function, frequency of
exacerbations and self-reported symptoms. Our study
project, symptom clusters and immune markers in
patients with COPD, included patients with stable
COPD, GOLD II–IV, in an outpatient clinic at hospitals
in the south-eastern area of Norway. Lung function tests,
questionnaires, blood tests and clinical tests were regis-
tered, and also at a one-year follow up. In total 267
patients were included, of which 30 patients (11.5%)
had IgG < 6.1. These patients were defined as hypo-
gamma-COPD. Subjects with hypogamma-COPD were
compared to the other COPD patients. In this group,
patients had lower FEV1 and a higher proportion had
GOLD stage IV; they also had a higher number of COPD
admissions, and treatment cures with antibiotics and
prednisolone in the last year. Moreover, patients with
hypogamma-COPD did not have a higher occurrence of
chronic bronchitis or variable obstruction. There was no
significant difference in the frequency of emphysema.
Importantly, we found that hypogamma-COPD was
related to the occurrence of acute exacerbations in the
preceding year, as well as a severe COPD grade.
New approaches of lung function measurements in
COPD
Linnea Jarenbäck, University of Lund, Sweden
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There are different phenotypes of COPD, e.g. bronchi-
tis, type of emphysema, bronchodilator responders and
frequent exacerbators. It is important to characterise
and clinically phenotype each individual, to aid the
development of more individualised therapies.
At the Lund University Hospital respiratory research
unit, we investigated baseline lung physiology para-
meters and reversibility pattern using advanced lung
function measurements (spirometry, body plethysmo-
graphy, impulse oscillometry, CO-diffusion and multi-
ple breath washout of N2) in smoking controls and
COPD patients. Our aim was to gain further insight
into the disease development and progression.
Furthermore, we aimed to improve respiratory care
for COPD patients, by identifying parameters impor-
tant for disease development, progression and therapy
response.
In June 2016, my thesis: ‘COPD- lung physiology
and genetic links’ was published. Data presented here
comprise the lung physiology section of this thesis. Our
main findings included: (1) FEV1%p did not correlate
with other lung function parameters within each
GOLD stage; (2) several parameters showed segmented
relationships over a linear relationship to FEV1%p, and
had break points where the disease pattern changed at
FEV1%p 60–70; (3) COPD patients showed increased
ventilation heterogeneity in the acinar airways which
was associated with decreased diffusion capacity, but
no response to bronchodilators; and (4) reversibility of
other lung function parameters did not always correlate
to the reversibility in FEV1%p, thus separating some
flow responders from volume or resistance responders.
Is singing efficient in COPD rehabilitation?
Mette Kaasgaard, Aarhus University Hospital,
Denmark
Aarhus University Hospital, Pulmonary Department
and Center for Music in the Brain, Clinical
Department, Aarhus University, Aarhus, Denmark
mette2706@gmail.com
After diagnosis, COPD patients are offered participa-
tion in pulmonary rehabilitation (PR) for the purpose
of better managing disease and symptoms and for
avoiding future relapses and hospitalisations. However
there are a large number of dropouts from the PR
programme, and a need for investigation of alternative
activities. We suggest group singing as such potential
relevant and motivating activity. Internationally sing-
ing therapy (ST) for COPD patients has been explored
with positive indications, and in Denmark it has
become common-sense that singing is healthy to
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COPD patients. However the field has not yet been
investigated in a Danish context.
We aim to examine the effects of 10-week interven-
tion based group singing. The main hypothesis of this
study is that singing might lead to a positive and
consistent rehabilitation process which regards physio-
logical as well as psychological and psychosocial para-
meters compared to current PR.
The study is amixedmethod study, primarily based on
a randomised controlled trial with three groups: singing,
singing and physical training, and an active control group
receiving physical training. Qualitative studies are also
part of the project. We aim to include 240 patients.
Group singing potentially leads to improvements
on individual patient level and to higher motivation in
relation to the rehabilitation programme. Also ST
might lead to less consumption of medicine, a
decrease in exacerbations and hospitalisations, and
as a result a decrease in national health care expenses.
In case of successful findings ST could therefore be
considered accepted within the national standard PR
programme.
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